Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis
Endocannabinoid System Mechanisms The endocannabinoid system (ECS) plays a pivotal role in maintaining homeostasis within the body and has garnered […]
Endocannabinoid System Mechanisms The endocannabinoid system (ECS) plays a pivotal role in maintaining homeostasis within the body and has garnered […]
Study Overview This research investigates the joint therapeutic effect of Akkermansia muciniphila and sodium butyrate on oxaliplatin-induced peripheral neuropathy, a
Study Overview This research focuses on understanding how genetic differences among individuals may influence the likelihood of experiencing adverse effects
Endocannabinoid System and Multiple Sclerosis The endocannabinoid system (ECS) consists of a network of receptors, endogenous cannabinoids, and metabolic enzymes
Mechanisms of Action The intervention involving Akkermansia muciniphila and sodium butyrate operates through several interconnected mechanisms that target the underlying
Case Studies and Observations Recent inquiries into the utilization of the endocannabinoid system for managing residual disease in relapse-free multiple
Background on Cardiovascular Disease and Traumatic Brain Injury Cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally,
Sex Differences in Cardiovascular Disease Outcomes After Traumatic Brain Injury Read Post »
Current Applications in Neurology Portable eye-tracking technology has found numerous practical applications within the field of neurology, significantly enhancing both
Portable eye-tracking in neurology: current uses and future perspectives in cognition Read Post »
Understanding Cardiovascular Outcomes The relationship between traumatic brain injury (TBI) and cardiovascular disease (CVD) outcomes has garnered increasing attention in
Sex Differences in Cardiovascular Disease Outcomes After Traumatic Brain Injury Read Post »
Study Overview The research investigated the use of subcutaneous efgartigimod for patients suffering from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a